Vestal Point Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Vestal Point Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-290,000	Closed	-$49.3M	–	102
2025 Q4	$49.3M	Sell	290,000 -210,000	-42%	-$32.2M	1.68%	19
2025 Q3	$65.9M	Sell	500,000 -700,000	-58%	-$84M	2.98%	10
2025 Q2	$127M	Buy	+1,200,000	New	+$130M	6.7%	2
2025 Q1	–	Sell	-975,000	Closed	-$120M	–	72
2024 Q4	$120M	Buy	975,000 +75,000	+8%	+$8.84M	7.12%	1
2024 Q3	$100M	Sell	900,000 -600,000	-40%	-$65.7M	7.6%	2
2024 Q2	$160M	Buy	1,500,000 +400,000	+36%	+$44M	11.94%	1
2024 Q1	$132M	Buy	1,100,000 +375,000	+52%	+$45.9M	10.95%	2
2023 Q4	$89.2M	Buy	+725,000	New	+$90.5M	9.45%	2

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vestal Point Capital's JAZZ Position: Q1 2026 in Review

Vestal Point Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 290,000 shares — an estimated $49.3M sold.

Vestal Point Capital first reported a position in JAZZ in Q4 2023 and held it in 8 quarters. The position peaked at $160M in Q2 2024. 575 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Vestal Point Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Vestal Point Capital sold 290,000 Jazz Pharmaceuticals shares in Q1 2026, an estimated $49.3M.
Vestal Point Capital first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Vestal Point Capital's Jazz Pharmaceuticals position peaked at $160M in Q2 2024.
575 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.